<span item_type="fundamental" item_id="1d8250df86e7808ac85185e547c022ae" counter_id="ST/US/CLDWW" env="prod"></span><span item_type="announcement" item_id="516116227467645697" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.18.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -5.062 M.</p><p></p><h3>Net Loss</h3><p>The company reported a net loss attributable to common stockholders of $5.0 million, or $0.18 per share, for the three months ended March 31, 2025, compared to a net loss of $7.2 million, or $2.03 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm"></span></p><h3>Research and Development Expenses</h3><p>Research and development expenses were $2.4 million for the three months ended March 31, 2025, compared to $2.7 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm"></span></p><h3>General and Administrative Expenses</h3><p>General and administrative expenses were $2.6 million for the three months ended March 31, 2025, compared to $4.0 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm"></span></p><h3>Cash and Restricted Cash</h3><p>The company had approximately $10.6 million in cash and $0.2 million in restricted cash as of March 31, 2025, compared to $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Calidi Biotherapeutics anticipates upcoming key milestones, including the reporting of interim clinical results and the dosing of patients. The company plans clinical trials and emphasizes the potential safety and efficacy of its therapeutic candidates in development. However, these forward-looking statements are subject to multiple risks and uncertainties that could cause actual results to differ materially.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/ex99-1.htm"></span></p>

CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM) | 8-K: FY2025 Q1 EPS: USD -0.18